Reports of impending layoffs, a buyout offer, and a return-to-office mandate have put a damper on FDA staff morale ...
Management targets JPY 65 billion-JPY 75 billion in capital expenditure per year over the medium term. We think its operating cash flow could support such a level of investments, but the dividend ...
In the face of tough competition from Apellis and a recent setback with prescribers, Astellas’ geographic atrophy (GA) med ...
Many consumer devices undergo the FDA clearance process, such as LED masks and fitness trackers that have features like ...
Commercials run by the telehealth company Hims & Hers have been placed under the microscope as lawmakers are calling out the advertisement of prescriptions for injectable weight-loss drugs without ...
Ersodetug, a novel, fully human monoclonal antibody for the treatment of hyperinsulinism (HI), receives Breakthrough Therapy Designation and ...
On December 27, 2024, the US Food and Drug Administration (FDA) published its final rule to update the definition for “healthy” claims on food ...
Data show Anaphylm maintains consistent stability and potency under extreme temperature and real-world conditions, including heat, freezing, and ...
Discover the latest developments in potential ALS treatments with COYA-302 and COYA-303, set to impact the $1.33 billion ...
The Week is part of Future US Inc, an international media group and leading digital publisher. Visit our corporate site.
The U.S. Food and Drug Administration has approved Journavx (suzetrigine) 50 milligram oral tablets, marking the introduction of a first-in-class non-opioid analgesic designed to treat moderate to ...
Vertex has set the therapy’s wholesale acquisition cost at $15.50 per 50mg pill. Credit: © 2025 Vertex Pharmaceuticals Incorporated. All Rights Reserved. The US ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback